 | Up a level |
Dunbar, Andrew J; Bowman, Robert L; Park, Young C; O'Connor, Kavi; Izzo, Franco; Myers, Robert M; Karzai, Abdul; Zaroogian, Zach; Kim, Won Jun; Fernandez-Maestre, Ines; Waarts, Michael R; Nazir, Abbas; Xiao, Wenbin; Codilupi, Tamara; Brodsky, Max; Farina, Mirko; Cai, Louise; Cai, Sheng F; Wang, Benjamin; An, Wenbin; ... (2024). Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms. Cancer discovery, 14(5), pp. 737-751. American Association for Cancer Research 10.1158/2159-8290.CD-22-0952
Codilupi, Tamara; Szybinski, Jakub; Arunasalam, Stefanie; Jungius, Sarah; Dunbar, Andrew C; Stivala, Simona; Brkic, Sime; Albrecht, Camille; Vokalova, Lenka; Yang, Julie L; Buczak, Katarzyna; Ghosh, Nilabh; Passweg, Jakob R; Rovo, Alicia; Angelillo-Scherrer, Anne; Pankov, Dmitry; Dirnhofer, Stephan; Levine, Ross L; Koche, Richard and Meyer, Sara C (2024). Development of resistance to type II JAK2 inhibitors in MPN depends on AXL kinase and is targetable. Clinical cancer research, 30(3), pp. 586-599. American Association for Cancer Research 10.1158/1078-0432.CCR-23-0163
